Clinical Trial

Radiation Therapy With Concomitant and Adjuvant Temozolomide Versus Radiation Therapy With Adjuvant PCV Chemotherapy in Patients With Anaplastic Glioma or Low Grade Glioma

Active, Not Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
Radiation therapy uses high-energy x-rays to kill tumor cells. Drugs used in chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. It is not yet known whether giving radiation with concomitant and adjuvant temozolomide versus radiation with adjuvant PCV is more effective in treating anaplastic glioma or low grade glioma.
Protocol Amendment History 145 amendments
This ClinicalTrials.gov record has been amended 145 times since 2009-04-22; most recent amendment 2026-01-20.
Status change: Recruiting → Active, Not Recruiting 2024-08-01
Status change: Suspended → Recruiting 2015-12-18
Status change: Recruiting → Suspended 2015-03-24
Status change: Not Yet Recruiting → Recruiting 2009-10-14
Trial Details
NCT Number NCT00887146
Lead Sponsor Alliance for Clinical Trials in Oncology
Collaborators: National Cancer Institute (NCI), European Organisation for Research and Treatment of Cancer - EORTC, Canadian Cancer Trials Group
Conditions Brain and Central Nervous System Tumors
Enrollment 305 participants
Start Date 2009-09
Primary Completion 2029-10-31 (estimated)
Study Completion 2029-10-31 (estimated)
Updated on ClinicalTrials.gov 2026-01-22